| View |
|
BR-893
|
Alglucosidase alfa
|
Myozyme
|
50 mg
|
Powder For Concentrate For Solutions For Infusion (IV)
|
Prescription Drug (RX)
|
Type I clear and colorless glass vial
|
-
|
Genzyme Ireland Limited
|
Ireland
|
N/A
|
Sanofi-Aventis Philippines, Inc.
|
Sanofi-Aventis Philippines, Inc.
|
Renewal
|
26 April 2023
|
31 January 2028
|
| View |
BR-896_PI_01.pdf
|
BR-896
|
Panitumumab
|
Vectibix
|
100 mg/5 mL (20 mg/mL)
|
Concentrate for Solution for Infusion (IV)
|
Prescription Drug (RX)
|
Single dose. 5 mL Type I glass vial with elastomeric rubber stopper and aluminum seal with flip-off cap (Box of 1's)
|
-
|
Amgen Manufacturing Limited
|
United States of America
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial (from Monitored Release)
|
30 March 2023
|
04 April 2026
|
| View |
|
BR-897
|
Human Norml Immunoglobulin
|
I.V. - Globulin Sn Injection
|
5,000mg/100mL
|
Solution For Injection (Iv)
|
Prescription Drug (RX)
|
Vial in a box
|
Immunoglobulin
|
Green Cross Corp.
|
Korea
|
|
Vizcarra Pharmaceutical, Inc.
|
Vizcarra Pharmaceutical, Inc.
|
BR-897
|
20 February 2023
|
04 April 2028
|
| View |
|
BR-901
|
Trivalent Seasonal Influenza Vaccine (Surface Antigen, Inactivated) 2024 Southern Hemisphere Strain
|
Influvac
|
Each dose (0.5 mL) contains the following strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain
15 ug HA**
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
15 ug HA**
(A/Thailand/8/2022, IVR-237)
B/Austria/1359417/2021-like strain
15 ug HA**
(B/Austria/1359417/2021, BVR-26)
*Propagated in embryonated chicken eggs **Haemagglutinin
|
Suspension for Injection (IM/SC)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL Type I pre-filled glass syringe with grey
bromobutyl rubber plunger with needle (Box of 1's).
|
Vaccines
|
Abbott Biologicals B.V.
|
Netherlands
|
|
Abbott Laboratories
|
Abbott Laboratories
|
Monitored Release (Strain Clearance)
|
14 February 2024
|
14 February 2025
|
| View |
BR-906_PI_01.pdf
|
BR-906
|
Golimumab
|
Simponi
|
50 mg/0.5 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
Pre-filled pen (Smartject) x 0.5 mL (Box of 1's)
|
-
|
Baxter Pharmaceutical Solutions LLC
|
United States of America
|
N/A
|
Johnson & Johnson (Phils.) Inc.
|
Johnson & Johnson (Phils.) Inc.
|
Initial
|
15 March 2022
|
14 May 2026
|
| View |
|
BR-907
|
Infliximab
|
Remsima
|
100mg
|
Lyophilized Powder for Concentrate for
Solution for Infusion (IV)
|
Prescription Drug (RX)
|
20 mL Type I glass vial (Box of 1's)
|
-
|
Celltrion, Inc. (Plant 2)
|
Korea
|
N/A
|
Celltrion Healthcare Philippines, Inc.
|
Celltrion Healthcare Philippines, Inc.
|
Renewal (Correction)
|
02 August 2023
|
14 May 2028
|
| View |
|
BR-898
|
Pneumococcal Conjugate Vaccine, 13-valent
(adsorbed)
|
Prevenar 13
|
Formulation: Each 0.5 mL dose contains:
Pneumococcal polysaccharide serotype 1*.....2.2 mcg Pneumococcal polysaccharide serotype 3*..............2.2 mcg Pneumococcal polysaccharide serotype 4* ......... .............2.2 mcg Pneumococcal polysaccharide serotype 5*..............2.2 mcg Pneumococcal polysaccharide serotype 6A*............... ...2.2 mcg Pneumococcal polysaccharide serotype 6B*........4.4 mcg Pneumococcal polysaccharide serotype 7F*..........2.2 mcg Pneumococcal polysaccharide serotype 9V* .........2.2 mcg Pneumococcal polysaccharide serotype 14*.............2.2mcg Pneumococcal polysaccharide serotype 18C*..............2.2 mcg Pneumococcal polysaccharide serotype 19A* .....................2.2 mcg Pneumococcal polysaccharide serotype 19F*....................2.2 mcg Pneumococcal polysaccharide serotype 23F* .....................2.2 mcg *Conjugated to CRM197 carrier protein and adsorbed on Aluminium phosphate (125 mcg Aluminum)
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 2 mL Type I Clear Glass Vial with Rubber Stopper, crimped with Aluminum Shell and White Flip off Cap with Vaccine Vial Monitor (Box of 50's)
|
-
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
N/A
|
Pfizer, Inc.
|
N/A
|
-
|
21 April 2021
|
04 April 2026
|
| View |
|
BR-909
|
Enoxaparin Sodium
|
Enoclex
|
60mg/0.6mL
|
Solution For Injection (SC)
|
Prescription Drug (Rx)
|
Type I pre-filled glass syringe x 0.6mL with needle, packed in PVC/PE/paper blister (Box of 2's)
|
Antithrombotic Agent
|
Shenzhen Techdow Pharmaceutical Co., Ltd.
|
China
|
|
Endure Medical, Inc.
|
|
Automatic Renewal
|
14 April 2023
|
21 May 2028
|
| View |
|
BR-911
|
LIVE ATTENUATED MEASLES, MUMPS and RUBELLA VACCINE
|
NONE
|
10 Dose
|
Freeze- Dried Powder For Injection ( S.C )
|
Prescription Drug (Rx)
|
50 amber glass vial of lyophilized powder per box + 5mL SWFI ( diluent ) in clear, colorless glass ampule per box of 50's
|
VACCINE
|
Serum Institute of India Ltd.
|
India
|
|
GENPHARM INC.
|
GENPHARM INC.
|
Renewal
|
21 March 2023
|
21 May 2028
|
| View |
|
BR-912
|
Aflibercept
|
Eylea
|
40 mg/mL (4 mg/100 mL)
|
Solution for Injection (IVT)
|
Prescription Drug (RX)
|
2 mL (Net content: 100uL) Type I colorless glass vial fitted with butyl rubber stopper, aluminum crimp seal and blue propylene flip-off cap + 18G 1 1/2" filter needle (Box of 1's)
|
-
|
Bayer AG
|
Germany
|
|
Bayer Philippines, Inc.
|
Bayer Philippines, Inc.
|
Initial [Variation]
|
04 December 2023
|
04 December 2028
|
| View |
|
BR-916
|
Choriogonadotropin Alfa
|
Ovidrel
|
250 mcg/0.5 mL
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
0.5 mL Pre-filled pen with 1 needle (Box of 1's)
|
-
|
Merck Serono S.p.A.
|
Italy
|
N/A
|
Merck, Inc.
|
Merck, Inc.
|
Renewal
|
31 March 2023
|
23 July 2028
|
| View |
|
BR-917
|
Measles, Mumps and Rubella Vaccine (Live,
Attenuated)
|
M-M-R II
|
REMARKS:
Formulation:
After reconstitution, each dose (0.5 mL) contains:
Live, attenuated virus derived from Edmonston B strain of measles………………… 3.0 log TCID50*
Live, attenuated Jeryl Lynn strain of mumps…………..4.1 log TCID50*
Live, attenuated Wistar RA27/3 strain of rubella. …………3.0 log TCID50*
*TCID 50 - Tissue Culture Infectivity Dose 50%
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
Prescription Drug (RX)
|
Single dose. 3 mL Type I clear glass vial + 0.5 mL clear glass vial (Sterile Water for Injection as diluent) (Box of 1's and 10's).
|
-
|
Merck Sharp and Dohme LLC
|
U.S.A
|
N/A
|
Merck Sharp & Dohme (I.A.) LLC
|
Merck Sharp & Dohme (I.A.) LLC
|
Renewal
|
26 April 2023
|
26 January 2028
|
| View |
|
BR-918
|
Clostridium Botulinum Toxin Type A
|
HugelTox
|
100 Units
|
Lyophilized Powder For Injection
|
Prescription Drug (RX)
|
5 ml nominal volume clear type I glass vial per box
|
Muscle Relaxant
|
Hugel, Inc.
|
Korea
|
|
H & B Pharma International, Inc.
|
H & B Pharma International, Inc.
|
Renewal
|
22 March 2023
|
07 August 2028
|
| View |
|
BR-919
|
Diphtheria, Tetanus, Pertussis (Acellular Component), Hepatitis B, Poliomyelitis (Inactivated) and Haemophilus influenzae Type B Conjugate Vaccine (Adsorbed)
|
Hexaxim
|
Formulation:
Each dose (0.5 mL) contains: Diphtheria toxoid'
Tetanus toxoid '
Bordetella pertussis antigen
Pertussis toxoid'
Filamentous hemagglutinin' Poliovirus (Inactivated)2.3 Type I (Mahoney) strain
NLT 20 IU NLT 40 IU
Hepatitis B surface antigen Haemophilus influenzae Type B
Polysaccharide Phosphate)
10 mcg
(Polyribosylribitol 12 mcg
Conjugate to Tetanus protein
22-36 mcg
25 mcg
25 mcg
40 D antigen units
Type II (MEF-1) strain"
Type III (Saukett) strain1
8 D antigen units
32 D antigen units
'adsorbed on aluminium hydroxide, hydrated (Al(OH)3)
2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
3adsorbed on aluminium phosphate (AIPO4)
*propagated in VERO cells
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL pre-filled glass syringe with 2 separate needles (Box of 1's). Single dose.
|
Vaccines
|
Sanofi Pasteur
|
France
|
N/A
|
Sanofi Pasteur, Inc.
|
Zuellig Pharma Corporation
|
Renewal
|
04 September 2023
|
29 August 2028
|
| View |
|
BR-920
|
Filgrastim (Recombinant Human Granulocyte Colony Stimulating Factor)
|
White-C
|
300 mcg/mL
|
Solution For Injection
|
Prescription Drug (RX)
|
1 mL Pre-filled glass syringe
|
Hematopoietic Growth Factor
|
Shandong Kexing Bioproducts Co., Ltd.
|
China
|
|
Goodfellow Pharma Corporation
|
Goodfellow Pharma Corporation
|
Renewal
|
27 December 2018
|
03 September 2028
|
| View |
|
BR-921
|
Human Rabie Immunoglobulin
|
H-Ryg
|
100IU/mL
|
Solution For Injection (IM)
|
Prescription Drug (RX)
|
Type I Borosilicate glass with butyl rubber stopper, crimped with aluminum seal and propylene cap x 2mL (Box of 1's)
|
Immunoglobulin
|
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
|
China
|
|
Global Pharmatrade
|
|
Automatic Renewal
|
07 January 2022
|
03 September 2026
|
| View |
|
BR-922
|
Human Tetanus Immunoglobulin
|
H-Tyg
|
100IU/mL
|
Solution For Injection (IM)
|
Prescription Drug (RX)
|
Type I borosilicate glass with butyl rubber stopper, crimped with aluminum seal and propylene cap x 2.5mL (Box of 1's)
|
Immunoglobulins
|
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
|
China
|
|
Global Pharmatrade
|
|
Automatic Renewal
|
07 January 2022
|
03 September 2026
|
| View |
|
BR-923
|
Japanese Encephalitis Vaccine (Live, Attenuated)
|
Imojev
|
Formulation: After reconstitution, one dose (0.5 mL) contains 4.0-5.8 log Plaque Forming Units (PFU) live, attenuated, recombinant Japanese Encephalitis Virus.
|
Powder for Suspension for Injection (SC)
|
Prescription Drug (RX)
|
Packaging: One box contains Type I glass vial (powder), 0.5 mL Type I glass vial (0.4% Sodium Chloride as diluent), each equipped with halobutyl stopper and an aluminum/propylene flip-off cap, with syringe and two needles. (Box of 1's).
|
-
|
Government Pharmaceutical Organization - Merieux Biological Products Co., Ltd.
|
Thailand
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial (Variation)
|
13 July 2022
|
13 July 2027
|
| View |
BR-924_PI_01.pdf
|
BR-924
|
Meningococcal Groups A, C, W-135 and Y Conjugate
Vaccine
|
Nimenrix
|
Formulation: After reconstitution, each dose (0.5 mL) contains: Neisseria meningitidis group A polysaccharide* Neisseria meningitidis group C polysaccharide* Neisseria meningitidis group W-135 polysaccharide* Neisseria meningitidis group Y polysaccharide*
5 mcg 5 mcg 5 mcg 5 mcg
* conjugated to tetanus toxoid carrier protein
44 mcg
|
Lyophilized Powder for Solution for Injection (IM)
|
Prescription Drug (Rx)
|
Type I clear glass vial + 0.5 mL pre-filled glass syringe
(0.9% Sodium Chloride as diluent) with 2 separate needles (Box of l’s)
|
-
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
|
Pfizer, Inc.
|
|
Initial (Variation)
|
03 August 2022
|
03 August 2027
|
| View |
|
BR-925
|
Human Papillomavirus Vaccine [Types 16 and 18]
(Recombinant, adjuvanted, adsorbed)
|
Cervarix
|
Formulation:
1 dose (0.5 mL) contains:
Human Papillomavirus type 16 L1 protein*.
Human Papillomavirus type 18 L1 protein*.
.20 mcg ...... 20 mcg
*adjuvanted by AS04 containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and Aluminum hydroxide, hydrated [Al(OH)3]
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
1 mL in 3 mL Type I Glass Vial with Vaccine Vial Monitor (Box of 1's and 100's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
N/A
|
GlaxoSmithKline Philippines, Inc.
|
GlaxoSmithKline Philippines, Inc.
|
Renewal (Reconstruction)
|
22 February 2024
|
23 March 2027
|